9th September 2026 Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies
8th September 2026 Ex-Legend CEO takes helm at MPM BioImpact-founded biotech startup scouring the globe for drugs
11th August 2026 K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing
